Scientists have made a groundbreaking discovery that could revolutionize the way we treat brain disorders. Researchers at MIT have created microscopic electronic devices, known as cell chips, which are "hitched" to immune cells and can travel through the bloodstream to reach specific areas of inflammation in the brain.
These tiny chips, measuring just 10 microns in diameter, are made from biocompatible materials and can be powered by infrared light. They were developed by a team led by Deblina Sarkar, an electrical engineer and MIT assistant professor, who has spent years working on this technology.
The innovation lies in the way these devices are linked to immune cells, called monocytes, which can home in on inflammation sites in the brain. By fusing the electronics with these cells, the researchers were able to solve three significant problems: making functional electronic devices smaller than blood cells, controlling them with magnetic fields, and crossing the blood-brain barrier.
The resulting solution, dubbed "circulatronics," is a hybrid of living cells and electronics that can be injected into the circulatory system. These hybrids have shown promising results in live mice, with most reaching their destination and causing significant neuronal activation when exposed to infrared light.
The potential applications of this technology are vast, from treating neurodegenerative diseases like Alzheimer's and glioblastoma, to developing brain-computer interfaces for healthy people. The devices can be designed to fully degrade after a set time, making them suitable for use in human clinical trials.
While there is still much work to be done, Sarkar and her team are optimistic that their innovation could one day help with placing implants in brain regions that were previously inaccessible through surgery. With the aim of getting these hybrids FDA-approved within the next three years, the researchers are excited about the prospect of harnessing this technology to improve human health.
These tiny chips, measuring just 10 microns in diameter, are made from biocompatible materials and can be powered by infrared light. They were developed by a team led by Deblina Sarkar, an electrical engineer and MIT assistant professor, who has spent years working on this technology.
The innovation lies in the way these devices are linked to immune cells, called monocytes, which can home in on inflammation sites in the brain. By fusing the electronics with these cells, the researchers were able to solve three significant problems: making functional electronic devices smaller than blood cells, controlling them with magnetic fields, and crossing the blood-brain barrier.
The resulting solution, dubbed "circulatronics," is a hybrid of living cells and electronics that can be injected into the circulatory system. These hybrids have shown promising results in live mice, with most reaching their destination and causing significant neuronal activation when exposed to infrared light.
The potential applications of this technology are vast, from treating neurodegenerative diseases like Alzheimer's and glioblastoma, to developing brain-computer interfaces for healthy people. The devices can be designed to fully degrade after a set time, making them suitable for use in human clinical trials.
While there is still much work to be done, Sarkar and her team are optimistic that their innovation could one day help with placing implants in brain regions that were previously inaccessible through surgery. With the aim of getting these hybrids FDA-approved within the next three years, the researchers are excited about the prospect of harnessing this technology to improve human health.